2002
DOI: 10.1046/j.1365-2141.2002.37694.x
|View full text |Cite
|
Sign up to set email alerts
|

Thalidomide treatment of relapsed multiple myeloma patients and changes in circulating VEGF and bFGF

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
1
0

Year Published

2003
2003
2011
2011

Publication Types

Select...
4
1

Relationship

0
5

Authors

Journals

citations
Cited by 6 publications
(1 citation statement)
references
References 4 publications
(2 reference statements)
0
1
0
Order By: Relevance
“…In addition, a direct relationship between VEGF production and leukemic blasts and malignant plasma cells proliferation has been established, thus anti-VEGF agents are being evaluated in many protocols. The anti-angiogenic activity of the drug may be due to a reduction of both VEGF and b-FGF (basic fibroblast growth factor) levels, although disconcordant findings have been reported [1]. Thalidomide was shown to be effective in relapsed or refractory multiple myeloma and its role as part of the initial treatment armamentarium is under investigation.…”
mentioning
confidence: 99%
“…In addition, a direct relationship between VEGF production and leukemic blasts and malignant plasma cells proliferation has been established, thus anti-VEGF agents are being evaluated in many protocols. The anti-angiogenic activity of the drug may be due to a reduction of both VEGF and b-FGF (basic fibroblast growth factor) levels, although disconcordant findings have been reported [1]. Thalidomide was shown to be effective in relapsed or refractory multiple myeloma and its role as part of the initial treatment armamentarium is under investigation.…”
mentioning
confidence: 99%